Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer

Urology

Volumn 55, Issue 4, 2000, Pages 572-577

  D'Amico, Anthony V ^d   Whittington, Richard ^b   Malkowicz, S Bruce ^b   Wu, Yue Hui ^c   Chen, Ming Hui ^c   Art, Meagan ^a   Tomaszewski, John E ^b   Wein, Alan ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c Life Science and Bioengineering Center   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER;

BIOPSY; HUMANS; LYMPH NODE EXCISION; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; REOPERATION; RISK ASSESSMENT; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 0034114745     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00479-3     Document Type: Article

References (18)

1. Partin A.W., Kattan M.W., Subong E.N.P., et al. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer a multi-institutional update . JAMA. 277:1997;1445-1452.
2. D'Amico A.V., Whittington R., Malkowicz S.B., et al. PSA failure despite pathologic organ confined disease the basis for an adjuvant therapy trial . J Clin Oncol. 15:1997;1465-1469.
3. Lerner S.E., Blute M.L., Bergstralh E.J., et al. Analysis of risk factors for progression in patients with pathologically organ confined prostate cancers after radical retropubic prostatectomy. J Urol. 156:1996;137-143.
4. Kupelian P., Katcher J., Levin H.S., et al. Stage T1-2 prostate cancer a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy . Int J Radiat Oncol Biol Phys. 37:1997;1043-1052.
5. D'Amico A.V., Whittington R., Kaplan I., et al. Equivalent biochemical failure free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of 4-20 ng/mL. Int J Radiat Oncol Biol Phys. 37:1997;1053-1058.
6. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974.
7. Kattan M.W., Easthan J.A., Stapleton A.M.F., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 90:1998;766-771.
8. D'Amico A.V., Whittington R., Malkowicz S.B., et al. A pre-treatment nomogram for prostate specific antigen recurrence following radical prostatectomy or external beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 17:1999;168-172.
9. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percent of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 18:1999;310a.
10. Tempany C.M., Zhou X., Zerhouni E.A., et al. Staging of prostate cancer results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques . Radiology. 192:1994;47-54.
11. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically localized prostate cancer. J Clin Oncol. 14:1996;1770-1777.
12. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
13. Gleason D.F. Histologic grading and staging of prostatic carcinoma. Tannenbaum M. Urologic Pathology. 1977;171-187 Lea & Febiger, Philadelphia.
14. Beahrs OH, Henson DE, Hutter RVP: American Joint Committee on Cancer, Manual for staging cancer, 4th ed. Philadelphia, JP Lippincott, 1997.
15. Oesterling J.E., Jacobsen S.J., Klee G.G., et al. Free, complexed and total serum prostate specific antigen the establishment of appropriate reference ranges for their concentrations and ratios . J Urol. 154:1995;1090-1095.
16. Cox D.R. Regression models and life tables. J Roy Stat Soc B. 34:1972;187-200.
17. Efron R, and Tibsherani R (Eds): An Introduction to the Bootstrap. New York, Chapman and Hall, 1993, pp 179-212.
18. Schemper M. The relative importance of prognostic factors in studies of survival. Stat Med. 12:1993;2377-2401.